Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals, Inc. (ARWR)
:ARWR
ARWR Analyst Ratings
Moderate Buy
7 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ARWR Stock 12 Month Forecast
Average Price Target
$40.60
▲(161.94% Upside)
| Highest Price Target$80.00 | Average Price Target$40.60 | Lowest Price Target$21.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Goldman Sachs
Reiterated
03/10/25
H.C. Wainwright
Reiterated
03/10/25
Morgan Stanley
Reiterated
03/10/25
Piper Sandler
Reiterated
02/26/25
B.Riley Financial
Reiterated
02/14/25
Citi
Downgraded
02/12/25
Chardan Capital
Reiterated
02/11/25
Leerink Partners
Reiterated
02/11/25
RBC Capital
Reiterated
02/11/25
Bank of America Securities
Reiterated
02/10/25
TD Cowen
―
Buy
―
Reiterated
02/10/25
Arrowhead Pharmaceuticals: Strategic Licensing Deal and Upcoming Drug Launch Drive Buy RatingWe maintain that the Ph3 data (see our notes her e and her e) reaffirm plozasiran as a solidly competitive ApoC3-lowering agent with favorable Q3M dosing over current SOCs and competitors and a clean safety profile. Management reaffirmed plans to launch plozasiran by late 2025 (assuming approval) with additional applications to other global regulatory agencies to follow shortly thereafter. We still expect marginal sales in FCS given the ultraorphan market size (<1K US patients) but view approval/launch as key in paving the way and bolstering the drug's competitive positioning for the much larger SHTG market (>3M US patients, $2-3B/yr in potential sales). BRENDAN SMITH, PH.D.
Bernstein
$24
Hold
54.84%
Upside
Reiterated
11/27/24
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Sanofi (Other OTC: SNYNF)
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Goldman Sachs
Reiterated
03/10/25
H.C. Wainwright
Reiterated
03/10/25
Morgan Stanley
Reiterated
03/10/25
Piper Sandler
Reiterated
02/26/25
B.Riley Financial
Reiterated
02/14/25
Citi
Downgraded
02/12/25
Chardan Capital
Reiterated
02/11/25
Leerink Partners
Reiterated
02/11/25
RBC Capital
Reiterated
02/11/25
Bank of America Securities
Reiterated
02/10/25
TD Cowen
―
Buy
―
Reiterated
02/10/25
Arrowhead Pharmaceuticals: Strategic Licensing Deal and Upcoming Drug Launch Drive Buy RatingWe maintain that the Ph3 data (see our notes her e and her e) reaffirm plozasiran as a solidly competitive ApoC3-lowering agent with favorable Q3M dosing over current SOCs and competitors and a clean safety profile. Management reaffirmed plans to launch plozasiran by late 2025 (assuming approval) with additional applications to other global regulatory agencies to follow shortly thereafter. We still expect marginal sales in FCS given the ultraorphan market size (<1K US patients) but view approval/launch as key in paving the way and bolstering the drug's competitive positioning for the much larger SHTG market (>3M US patients, $2-3B/yr in potential sales). BRENDAN SMITH, PH.D.
Bernstein
$24
Hold
54.84%
Upside
Reiterated
11/27/24
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Sanofi (Other OTC: SNYNF)
ARWR Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
11
12
15
17
13
Buy
4
3
2
1
1
Hold
11
9
7
4
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
26
24
24
22
19
Each month's total comprises the sum of three months' worth of ratings.
ARWR Financial Forecast
ARWR Stock Forecast FAQ
What is ARWR’s average 12-month price target, according to analysts?
Based on analyst ratings, Arrowhead Pharmaceuticals, Inc.’s 12-month average price target is $40.60.
What is ARWR’s upside potential, based on the analysts’ average price target?
Arrowhead Pharmaceuticals, Inc. has 161.94% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ARWR a Buy, Sell or Hold?
Arrowhead Pharmaceuticals, Inc. has a consensus rating of Moderate Buy which is based on 7 buy ratings, 4 hold ratings and 0 sell ratings.
What is Arrowhead Pharmaceuticals, Inc.’s price target?
The average price target for Arrowhead Pharmaceuticals, Inc. is $40.60. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $21.00. The average price target represents 161.94% Increase from the current price of $15.5.
The highest analyst price target is $80.00 ,the lowest forecast is $21.00. The average price target represents 161.94% Increase from the current price of $15.5.
What do analysts say about Arrowhead Pharmaceuticals, Inc.?
Arrowhead Pharmaceuticals, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of ARWR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.